Chemical Structure : JH-RE-06
CAS No.: 1361227-90-8
Catalog No.: PC-72501Not For Human Use, Lab Use Only.
JH-RE-06 is a potent REV1-REV7 interface inhibitor (IC50=0.78 uM, Kd=0.42 uM) that disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ, induces REV1 dimerization and blocks POLζ recruitment.
Packing | Price | Stock | Quantity |
---|---|---|---|
10 mg | $158 | In stock | |
25 mg | $258 | In stock | |
50 mg | $428 | In stock | |
100 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
JH-RE-06 is a potent REV1-REV7 interface inhibitor (IC50=0.78 uM, Kd=0.42 uM) that disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ, induces REV1 dimerization and blocks POLζ recruitment.
JH-RE-06 enhances cisplatin cytotoxicity and suppresses cisplatin-induced mutagenesis by interfering with REV1-dependent mutagenic TLS.
JH-RE-06 sensitizes cells to cisplatin and reduces HPRT mutations in a REV1-dependent manner.
JH-RE-06 (1.6 mg/kg, i.p.) improves tumor cell response to cisplatin in a xenograft mouse model.
JH-RE-06 is a novel TLS inhibitor as a class of chemotherapy adjuvants.
M.Wt | 468.72 | |
Formula | C20H16Cl3N3O4 | |
Appearance | Solid | |
Storage |
|
|
Solubility |
10 mM in DMSO |
|
Chemical Name/SMILES |
4(1H)-Quinolinone, 8-chloro-2-[(2,4-dichlorophenyl)amino]-3-(3-methyl-1-oxobutyl)-5-nitro- |
1. Wojtaszek JL, et al. Cell. 2019 Jun 27;178(1):152-159.e11.
2. Chatterjee N, et al. Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):28918-28921.
3. Taglialatela A, et al. Mol Cell. 2021 Oct 7;81(19):4008-4025.e7.
4. Chen Y, et al. Cell Death Dis. 2022 Feb 3;13(2):110.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright